Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastrointestinal Cancer

Urothelial Cancer

Prostate Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.

Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies 

Pelabresib plus ruxolitinib demonstrated a 35% or greater reduction in spleen volume and trended toward reducing mean absolute total symptom score (TSS) as well as improving TSS reduction by 50% at 24 weeks in patients with JAK inhibitor–naive myelofibrosis.

Pelabresib/Ruxolitinib Combo Improves Splenomegaly, TSS in JAK Inhibitor–Naive Myelofibrosis

Patients with relapsed/refractory follicular lymphoma experienced durable responses when treated with tisagenlecleucel (Kymriah) in the phase 2 ELARA study (NCT03568461), according to data presented at the 2023 ASH Annual Meeting.

Tisagenlecleucel Yields Durable Responses in R/R Follicular Lymphoma

Treatment with ruxolitinib led to prolonged failure-free survival and improved disease control vs best available treatment in patients with either steroid-refractory or -dependent chronic graft-vs-host disease.

Ruxolitinib Shows Sustained Efficacy Over Best Available Therapy in Steroid-Refractory/Dependent cGVHD

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements And Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Print Subscription

eNewsletter

Articles

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health has appointed Louise Ligresti, MD, as chief of Cancer Survivorship at New Jersey’s leading cancer center and the only one in the state designated as a Comprehensive Cancer Center by the National Cancer Institute.

New Chief of Cancer Survivorship Named to New Jersey’s Only NCI-Designated Comprehensive Cancer Center


Gina Mauro is your lead editorial contact for 

. She joined the company in 2015 and has held various positions on 

; she is also the on-air correspondent for 

. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: 

 feature article efforts and specializes in social issues and equality in oncology. Prior to joining the company in early 2020, she worked as an editor in numerous industries, including media, marketing, hospitality, and computer science, and freelanced in subjects such as history, culture, and the natural sciences.

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

2024 nominations are open for Giants of Cancer Care® 

In-person and virtual events just for HCPs

REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Share your views with OncChats 

Specialty

Expert oncologists review key datasets in leukemia & lymphoma that were presented at the ASCO 2022 and EHA 2022 Annual Meetings.

Leukemia & Lymphoma: A Review of Data from the ASCO 2022 and EHA 2022 Meetings

Videos

Expert oncologist perspectives on key clinical trial data in acute lymphocytic leukemia from the ASCO 2022 and EHA 2022 Annual Meetings.

Acute Lymphocytic Leukemia Trial Data From the ASCO 2022 and EHA 2022 Annual Meetings

Shared insight from expert oncologists on key clinical trial data in lymphomas from the ASCO 2022 and EHA 2022 Annual Meetings.

Lymphomas Trial Data From the ASCO 2022 and EHA 2022 Annual Meetings 

Leukemia & Lymphoma: A Review of Data from the ASCO 2022 and EHA 2022 Meetings

Latest Conference Coverage